Skip to content

Lactose monohydrate

DRUG20 trials

Sponsors

University Medical Center Utrecht, Sling Therapeutics Inc., Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, Karolinska Institutet, Inventiva

Conditions

(Chronic) Peripheral (occlusive) arterial disease (PAD)Acute CMV HepatitisAcute EBV HepatitisAcute Hepatitis AAcute Hepatitis BAcute Hepatitis CAcute Hepatitis EAcute ischemic stroke

Phase 2

Phase 3

Rhodiola Rosea Therapy of Major Depressive Disorder
CompletedNCT01098318
University of PennsylvaniaDepression
Start: 2010-06-30End: 2013-07-31Updated: 2018-02-22
Amantadine for COVID-19
NCT04894617
Copenhagen University Hospital, HvidovreCovid19
Start: 2021-06-01End: 2022-04-30Target: 226Updated: 2021-10-06
A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke
SuspendedCTIS2023-506178-11-00
Karolinska InstitutetAcute ischemic stroke
Start: 2025-11-11Target: 680Updated: 2023-11-07
PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3)
Not yet recruitingCTIS2024-514837-39-00
Centre Hospitalier Universitaire RouenPatients with obstructive sleep apnea syndrome with arterial hypertension
Target: 24Updated: 2024-07-01
CLEAR-PATH A randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty
Not yet recruitingCTIS2024-513363-15-01
Universitair Medisch Centrum Utrecht(Chronic) Peripheral (occlusive) arterial disease (PAD)
Target: 1696Updated: 2025-08-14
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Active, not recruitingCTIS2023-508248-23-00
InventivaNon-alcoholic steatohepatitis (NASH)
Start: 2021-11-26Target: 236Updated: 2025-11-10
A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SPIRONOLACTONE FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) - ALDORA
RecruitingCTIS2024-516884-10-00
Les Hopitaux Universitaires De StrasbourgRHEUMATOID ARTHRITIS
Start: 2022-06-22Target: 153Updated: 2024-09-11
Evaluating oral peri-operative acetylsalicylic acid in subjects undergoing endovascular coiling-only of unruptured brain aneurysms (EVOLVE)
RecruitingCTIS2024-517674-23-00
University Of CalgarySubjects undergoing elective endovascular coiling-only repair of unruptured brain aneurysms.
Start: 2023-05-05Target: 200Updated: 2025-04-15
HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Active, not recruitingCTIS2022-502832-37-00
Hemato-Oncologie voor Volwassenen Nederland (Hovon) StichtingAcute myeloid leukemia, Myelodysplastic syndrome
Start: 2019-03-01Target: 852Updated: 2025-07-02
Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series
Not yet recruitingCTIS2024-514012-28-00
Amsterdam UMC StichtingGaucher disease type 3
Target: 4Updated: 2024-11-25
Melatonin for patients with chronic low back pain (MELBACK) - a randomized placebo-controlled trial
RecruitingCTIS2024-514769-20-00
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Chronic low back pain
Start: 2025-03-02Target: 240Updated: 2025-01-15
Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial PALADIN [PeripherAL Arterial DIsease Network] -DAPTCLTI
Not yet recruitingCTIS2025-524297-42-00
Fondation Hopital Saint JosephCLTI defined as Rutherford category 4 or 5
Target: 614Updated: 2026-03-05

Phase 4

Unknown Phase

Related Papers